Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motireb in Functional Dyspepsia
NCT02831543Phase 3Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rebamipide in functional dyspepsia (FD) (3 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: The responder ratio of Global Overall Symptom at 4 weeks. Status: unknown.
02
Drugs
rebamipide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT02831543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831543.